Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genmab Ord Shs GNMSF

Healthcare Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA... see more

Recent & Breaking News (OTCPK:GNMSF)

Genmab Reaches Fourth Milestone in Lundbeck Collaboration

Globe Newswire December 6, 2013

Genmab Announces Expansion of DuoBody Platform Collaboration with Janssen Biotech, Inc.

Globe Newswire December 4, 2013

Genmab Reaches First Milestone in Daratumumab Collaboration With Janssen & Improves 2013 Financial Guidance

Globe Newswire November 26, 2013

Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2013

Globe Newswire November 13, 2013

Genmab to Present Product and Proprietary Technology data at American Society of Hematology Annual Meeting (ASH)

Globe Newswire November 7, 2013

Genmab Announces Financial Results for the First Nine Months of 2013

Globe Newswire November 6, 2013

Arzerra(r) Third Quarter 2013 Net Sales Figures

Globe Newswire October 23, 2013

GSK and Genmab Announce Submission to US Regulatory Authorities for Arzerra(r) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Globe Newswire October 18, 2013

OTCM ADR Index Up 11.12% in Q3 2013, 12.75% Year-to-Date

PR Newswire October 17, 2013

Genmab Announces Positive Top-Line Phase II Results of Ofatumumab in Multiple Sclerosis

Globe Newswire October 10, 2013

FDA Grants GSK and Genmab's Arzerra(R) (Ofatumumab) Breakthrough Therapy Designation for Previously Untreated Chronic Lymphocytic Leukemia

Globe Newswire September 13, 2013

Genmab Announces New Study of Daratumumab in Double Refractory Multiple Myeloma

Globe Newswire September 10, 2013

Genmab Reaches Milestone in DuoBody Platform Collaboration With Janssen

Globe Newswire August 26, 2013

Genmab Announces Financial Results for the First Half of 2013 and Improves 2013 Financial Guidance

Globe Newswire August 14, 2013

Arzerra(R) Second Quarter 2013 Net Sales Figures

Globe Newswire July 24, 2013

Genmab Files IND for HuMax-TF-ADC

Globe Newswire July 18, 2013

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Globe Newswire July 15, 2013

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Globe Newswire July 4, 2013

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhead

Globe Newswire June 17, 2013

Teprotumumab Restarts Clinical Development in New Indication

Globe Newswire June 11, 2013